Literature DB >> 8800108

Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?

J K Mickelson1, N M Lakkis, G Villarreal-Levy, B J Hughes, C W Smith.   

Abstract

OBJECTIVES: The purpose of this pilot study was to determine whether leukocyte activation occurs, whether leukocyte-platelet complexes develop and whether there is any association between these findings and clinical outcome after coronary angioplasty.
BACKGROUND: Increased expression of CD11b on monocytes and neutrophils promotes their adhesion to endothelial cells, extracellular matrix and smooth muscle cells. Thrombin-activated platelets adhere to monocytes and neutrophils through P-selectin. These cell complexes may affect the inflammatory process and, thus, the outcome of coronary angioplasty.
METHODS: During elective single-vessel coronary angioplasty in 11 men, samples were obtained for flow cytometric detection of CD11b, as well as the percent of leukocytes with adherent platelets and the intensity of bound platelet fluorescence (number of platelets/leukocyte).
RESULTS: After angioplasty, there was an increase in CD11b (monocytes: p = 0.001, neutrophils: p = 0.02) and leukocytes with adherent platelets (p = 0.02). During follow-up, five patients remained in stable condition and six had subsequent clinical events: restenosis and progression of disease requiring coronary artery bypass grafting (n = 3), myocardial infarction involving the dilated artery (n = 1) and unstable angina (n = 2). Values for leukocyte CD11b expression, the percent of leukocytes with adherent platelets and the intensity of bound platelet fluorescence were higher both before and after angioplasty in the six patients experiencing clinical events.
CONCLUSIONS: Despite standard aspirin and heparin therapy, leukocyte activation with platelet adherence occurs after coronary angioplasty. The magnitude of leukocyte activation and platelet adherence appears to be higher in patients experiencing late clinical events.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8800108     DOI: 10.1016/0735-1097(96)00164-7

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  46 in total

Review 1.  Antithrombotic therapy in the cardiac catheterization laboratory: focus on antiplatelet agents.

Authors:  M I Furman; A L Frelinger III; A D Michelson
Journal:  Curr Cardiol Rep       Date:  2000-09       Impact factor: 2.931

2.  Recombinant P-selectin glycoprotein-ligand-1 delays thrombin-induced platelet aggregation: a new role for P-selectin in early aggregation.

Authors:  Jean-François Théorêt; Wissam Chahrour; Daniel Yacoub; Yahye Merhi
Journal:  Br J Pharmacol       Date:  2006-06       Impact factor: 8.739

3.  Neutrophil accumulation on activated, surface-adherent platelets in flow is mediated by interaction of Mac-1 with fibrinogen bound to alphaIIbbeta3 and stimulated by platelet-activating factor.

Authors:  C Weber; T A Springer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Effect of Colchicine on Platelet-Platelet and Platelet-Leukocyte Interactions: a Pilot Study in Healthy Subjects.

Authors:  Binita Shah; Nicole Allen; Bhisham Harchandani; Michael Pillinger; Stuart Katz; Steven P Sedlis; Christina Echagarruga; Svetlana Krasnokutsky Samuels; Pajazit Morina; Prabhjot Singh; Liza Karotkin; Jeffrey S Berger
Journal:  Inflammation       Date:  2016-02       Impact factor: 4.092

5.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

Review 6.  Current concepts of platelet activation: possibilities for therapeutic modulation of heterotypic vs. homotypic aggregation.

Authors:  Gabriella Passacquale; Albert Ferro
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

7.  Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention.

Authors:  Binita Shah; Jeffrey S Berger; Nicholas S Amoroso; Xingchen Mai; Jeffrey D Lorin; Ann Danoff; Arthur Z Schwartzbard; Iryna Lobach; Yu Guo; Frederick Feit; James Slater; Michael J Attubato; Steven P Sedlis
Journal:  Am J Cardiol       Date:  2014-02-12       Impact factor: 2.778

8.  Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: insights from the EPIC, EPILOG, and EPISTENT trials.

Authors:  H S Gurm; D L Bhatt; A M Lincoff; J E Tcheng; D J Kereiakes; N S Kleiman; G Jia; E J Topol
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

9.  A mAb to the beta2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits.

Authors:  C Rogers; E R Edelman; D I Simon
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 10.  Leukocyte integrins and their ligand interactions.

Authors:  Young-Min Hyun; Craig T Lefort; Minsoo Kim
Journal:  Immunol Res       Date:  2009-01-29       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.